Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Tuberculosis

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 196 articles: HTML format Text format

Single Articles

June 2018
1. HORITA Y, Alsultan A, Kwara A, Antwi S, et al
   Evaluation of the Adequacy of WHO revised Dosages of the First-Line Anti-Tuberculosis Drugs in Children with Tuberculosis using Population Pharmacokinetic Modeling and Simulations.
   Antimicrob Agents Chemother. 2018 Jun 18. pii: AAC.00008.
   PubMed     Text format     Abstract available
   
   
   
2. DE MIRANDA SILVA C, Hajihosseini A, Myrick J, Nole J, et al
   Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log-Phase, Acid-Phase and Non-Replicating-Persister (NRP)-Phase in an In vitro Assay.
   Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00856.
   PubMed     Text format     Abstract available
   
   
   
3. DRUSANO GL, Myrick J, Maynard M, Nole J, et al
   Linezolid Kills Acid Phase and Non-replicative Persister Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model.
   Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00221.
   PubMed     Text format     Abstract available
   
   
   May 2018
4. ZONG Z, Jing W, Shi J, Wen S, et al
   Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China.
   Antimicrob Agents Chemother. 2018 May 29. pii: AAC.00165.
   PubMed     Text format     Abstract available
   
   
   
5. SHOEN C, DeStefano M, Hafkin B, Cynamon M, et al
   In vitro and in vivo activity of contezolid (MRX-I) against Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2018 May 21. pii: AAC.00493.
   PubMed     Text format     Abstract available
   
   
   
6. AMMERMAN NC, Swanson RV, Bautista EM, Almeida DV, et al
   Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
   Antimicrob Agents Chemother. 2018 May 7. pii: AAC.00636.
   PubMed     Text format     Abstract available
   
   
   
7. KAUFMANN SHE
   Indole Propionic Acid: a Small Molecule Links between Gut Microbiota and Tuberculosis.
   Antimicrob Agents Chemother. 2018;62.
   PubMed     Text format    
   
   
   April 2018
8. SHI W, Chen J, Zhang S, Zhang W, et al
   Identification of novel mutations in LprG (rv1411c), rv0521,rv3630, rv0010c, ppsC,cyp128 associated with pyrazinoic acid/pyrazinamide resistance in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2018 Apr 23. pii: AAC.00430.
   PubMed     Text format     Abstract available
   
   
   
9. BOOT M, Commandeur S, Subudhi AK, Bahira M, et al
   Accelerating early anti-tuberculosis drug discovery by creating mycobacterial indicator strains that predict mode of action.
   Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00083.
   PubMed     Text format     Abstract available
   
   
   
10. ZHENG H, Williams JT, Coulson GB, Haiderer ER, et al
    HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02459.
    PubMed     Text format     Abstract available
    
    
    
11. LIU Y, Pertinez H, Davies GR, Gillespie SH, et al
    Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00190.
    PubMed     Text format     Abstract available
    
    
    
12. LYONS MA
    Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02359.
    PubMed     Text format     Abstract available
    
    
    
13. STEFAN MA, Ugur FS, Garcia GA
    SOURCE OF THE FITNESS DEFECT IN RIFAMYCIN-RESISTANT M. TUBERCULOSIS RNA POLYMERASE AND THE MECHANISM OF COMPENSATION BY MUTATIONS IN THE beta'-SUBUNIT.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00164.
    PubMed     Text format     Abstract available
    
    
    February 2018
14. GUPTA R, Felix CR, Akerman MP, Akerman KJ, et al
    Gold(III) macrocycles and chelates targeting Mycobacterium tuberculosis and Mycobacterium abscessus: evidence for inhibition of topoisomerase 1A.
    Antimicrob Agents Chemother. 2018 Feb 26. pii: AAC.01696.
    PubMed     Text format     Abstract available
    
    
    
15. CHEN C, Gardete S, Jansen RS, Shetty A, et al
    Verapamil targets membrane energetics in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02107.
    PubMed     Text format     Abstract available
    
    
    
16. HEMANTH KUMAR AK, Kumar A, Kannan T, Bhatia R, et al
    Pharmacokinetics of second-line anti-tuberculosis drugs in children with multidrug-resistant tuberculosis in India.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02410.
    PubMed     Text format     Abstract available
    
    
    
17. WEINER M, Gelfond J, Johnson-Pais TL, Engle M, et al
    Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.01802.
    PubMed     Text format     Abstract available
    
    
    
18. ZUUR MA, Ghimire S, Bolhuis MS, Wessels AMA, et al
    The Pharmacokinetics of 2000 mg Ertapenem in Tuberculosis Patients.
    Antimicrob Agents Chemother. 2018 Feb 12. pii: AAC.02250.
    PubMed     Text format     Abstract available
    
    
    
19. CHEN Y, Yuan Z, Shen X, Wu J, et al
    Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.
    Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02259.
    PubMed     Text format     Abstract available
    
    
    
20. SAO EMANI C, Williams MJ, Wiid I, Baker B, et al
    Compounds with potential activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02236.
    PubMed     Text format     Abstract available
    
    
    January 2018
21. WANG Q, Pang Y, Jing W, Liu Y, et al
    Clofazimine for Treatment of Pulmonary Extensively Drug-Resistant Tuberculosis in China.
    Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02149.
    PubMed     Text format     Abstract available
    
    
    
22. HUO F, Luo J, Shi J, Zong Z, et al
    Increasing Prevalence of Rifampicin-Resistant Mycobacterium tuberculosis is Associated with the Transmission of Strains Harboring Compensatory Mutations in China: A 10-year Comparative Analysis.
    Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02303.
    PubMed     Text format     Abstract available
    
    
    
23. DIJKSTRA JA, van der Laan T, Akkerman OW, Bolhuis MS, et al
    In vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin.
    Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01724.
    PubMed     Text format     Abstract available
    
    
    
24. YU X, Zeng X, Shi W, Hu Y, et al
    The validation of Cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing, China.
    Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01824.
    PubMed     Text format     Abstract available
    
    
    
25. VILCHEZE C, Kim J, Jacobs WR Jr
    Vitamin C potentiates the killing of Mycobacterium tuberculosis by the first-line tuberculosis drugs isoniazid and rifampicin in mice.
    Antimicrob Agents Chemother. 2018 Jan 3. pii: AAC.02165.
    PubMed     Text format     Abstract available
    
    
    
26. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
    Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".
    Antimicrob Agents Chemother. 2017;62.
    PubMed     Text format    
    
    
    December 2017
27. DOMPREH A, Tang X, Zhou J, Yang H, et al
    Effect of genetic variation of NAT2 on isoniazid, SLCO1B1, and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis.
    Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.02099.
    PubMed     Text format     Abstract available
    
    
    
28. AUNG WW, Ei PW, Nyunt WW, Htwe MM, et al
    Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Myanmar.
    Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.01984.
    PubMed     Text format     Abstract available
    
    
    
29. SARATHY JP, Via LE, Weiner D, Blanc L, et al
    Extreme drug tolerance of Mycobacterium tuberculosis in caseum.
    Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.02266.
    PubMed     Text format     Abstract available
    
    
    
30. LEE H, Ahn S, Hwang NY, Jeon K, et al
    Limited Effect of Later-generation Fluoroquinolones in the Treatment of Ofloxacin-resistant and Moxifloxacin-susceptible Multidrug-resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.01784.
    PubMed     Text format     Abstract available
    
    
    November 2017
31. DESHPANDE D, Srivastava S, Bendet P, Martin KR, et al
    On the antibacterial and sterilizing effect of benzylpenicillin in tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.02232.
    PubMed     Text format     Abstract available
    
    
    
32. ABBADI BL, Villela AD, Rodrigues-Junior VS, Subtil FT, et al
    Revisiting activation of and the mechanism of resistance to the compound IQG-607 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 20. pii: AAC.02222.
    PubMed     Text format     Abstract available
    
    
    
33. DENTI P, Garcia-Prats AJ, Draper HR, Wiesner L, et al
    Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01521.
    PubMed     Text format     Abstract available
    
    
    
34. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, et al
    Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.00420.
    PubMed     Text format     Abstract available
    
    
    
35. HEYCKENDORF J, Andres S, Koser CU, Olaru ID, et al
    What is resistance? Impact of phenotypic versus molecular drug resistance testing on multi- and extensively drug-resistant tuberculosis therapy.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01550.
    PubMed     Text format     Abstract available
    
    
    October 2017
36. SUN Q, Xiao TY, Liu HC, Zhao XQ, et al
    Mutations within embCAB are associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01279.
    PubMed     Text format     Abstract available
    
    
    
37. WILLBY MJ, Wijkander M, Havumaki J, Johnson K, et al
    Detection of Mycobacterium tuberculosis pncA mutations by the NIPRO GenoscholarPZA-TB II as compared to conventional sequencing.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01871.
    PubMed     Text format     Abstract available
    
    
    
38. BERUBE BJ, Parish T
    Combinations of respiratory chain inhibitors have enhanced bactericidal activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01677.
    PubMed     Text format     Abstract available
    
    
    
39. GENESTET C, Ader F, Pichat C, Lina G, et al
    Combined Antibacterial Effect of Isoniazid and Rifampicin on Four Mycobacterium tuberculosis Strains: in Vitro Experiments and Response-Surface Modeling.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01413.
    PubMed     Text format     Abstract available
    
    
    
40. XU J, Tasneen R, Peloquin CA, Almeida DV, et al
    Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01692.
    PubMed     Text format     Abstract available
    
    
    
41. DE WELZEN L, Eldholm V, Maharaj K, Manson AL, et al
    Whole transcriptome and genomic analysis of extensively drug-resistant Mycobacterium tuberculosis clinical isolates identifies downregulation of ethA as a mechanism of ethionamide resistance.
    Antimicrob Agents Chemother. 2017 Oct 9. pii: AAC.01461.
    PubMed     Text format     Abstract available
    
    
    
42. NAKATANI Y, Opel-Reading HK, Merker M, Machado D, et al
    Role of alanine racemase mutations in Mycobacterium tuberculosis D-cycloserine resistance.
    Antimicrob Agents Chemother. 2017 Oct 2. pii: AAC.01575.
    PubMed     Text format     Abstract available
    
    
    September 2017
43. XU W, DeJesus MA, Rucker N, Engelhart CA, et al
    Chemical genomic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01334.
    PubMed     Text format     Abstract available
    
    
    
44. KIDWAI S, Park CY, Mawatwal S, Tiwari P, et al
    The dual mechanism of action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00969.
    PubMed     Text format     Abstract available
    
    
    
45. METCALFE JZ, Streicher E, Theron G, Colman RE, et al
    Mycobacterium tuberculosis subculture results in loss of potentially clinically relevant heteroresistance.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00888.
    PubMed     Text format     Abstract available
    
    
    
46. HUSZAR S, Singh V, Polcicova A, Barath P, et al
    N-Acetylglucosamine-1-phosphate transferase, WecA, as a validated drug target in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01310.
    PubMed     Text format     Abstract available
    
    
    
47. PARK SW, Tasneen R, Converse PJ, Nuermberger EL, et al
    Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01502.
    PubMed     Text format     Abstract available
    
    
    
48. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
    Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    
49. ARORA K, Ochoa-Montano B, Tsang PS, Blundell TL, et al
    Correction for Arora et al., "Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    July 2017
50. MOOSA A, Lamprecht DA, Arora K, Barry CE 3rd, et al
    Susceptibility of Mycobacterium tuberculosis cytochrome bd oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c.
    Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01338.
    PubMed     Text format     Abstract available
    
    
    
51. MCNEIL MB, Dennison D, Shelton C, Parish T, et al
    In vitro isolation and characterization of oxazolidinone resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01296.
    PubMed     Text format     Abstract available
    
    
    
52. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
    Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.01066.
    PubMed     Text format     Abstract available
    
    
    
53. MOURIK BC, de Knegt GJ, Verbon A, Mouton JW, et al
    Assessment of bactericidal drug activity and treatment outcome in a mouse tuberculosis model using a clinical Beijing strain.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00696.
    PubMed     Text format     Abstract available
    
    
    
54. PANG Y, Zong Z, Huo F, Jing W, et al
    In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00900.
    PubMed     Text format     Abstract available
    
    
    
55. YANG SS, Hu YB, Wang XD, Gao YR, et al
    Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 17. pii: AAC.00551.
    PubMed     Text format     Abstract available
    
    
    
56. VAN RIJN SP, Srivastava S, Wessels MA, van Soolingen D, et al
    The sterilizing effect of ertapenem-clavulanate in a hollow fiber model of tuberculosis and implications on clinical dosing.
    Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.02039.
    PubMed     Text format     Abstract available
    
    
    
57. ZIMMERMAN M, Lestner J, Prideaux B, O'Brien P, et al
    Ethambutol partitioning in tuberculous pulmonary lesions explains its clinical efficacy.
    Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00924.
    PubMed     Text format     Abstract available
    
    
    
58. PATEL N, O'Malley T, Zhang YK, Xia Y, et al
    A novel 6-benzyl ether benzoxaborole is active against Mycobacterium tuberculosis in vitro.
    Antimicrob Agents Chemother. 2017 Jul 3. pii: AAC.01205.
    PubMed     Text format     Abstract available
    
    
    June 2017
59. BABLISHVILI N, Tukvadze N, Shashkina E, Mathema B, et al
    The impact of gyrB and eis mutations in improving second-line drug resistance detection among Mycobacterium tuberculosis isolates from Georgia.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.01921.
    PubMed     Text format     Abstract available
    
    
    
60. LI SY, Tasneen R, Tyagi S, Soni H, et al
    Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin and pyrazinamide in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00913.
    PubMed     Text format     Abstract available
    
    
    
61. RAHMAN A, Ferdous SS, Ahmed S, Rahman SMM, et al
    Pyrazinamide susceptibility and pncA mutation profile of Mycobacterium tuberculosis among multi-drug resistant tuberculosis patients in Bangladesh.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00511.
    PubMed     Text format     Abstract available
    
    
    
62. CHIREHWA MT, McIlleron H, Rustomjee R, Mthiyane T, et al
    Pharmacokinetics of Pyrazinamide: optimising dosing regimens for drug-sensitive and -resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00490.
    PubMed     Text format     Abstract available
    
    
    
63. RODRIGUES FELIX C, Gupta R, Geden S, Roberts J, et al
    Selective Killing Of Dormant Mycobacterium tuberculosis By Marine Natural Products.
    Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00743.
    PubMed     Text format     Abstract available
    
    
    
64. ZHANG Y, Zhang J, Cui P, Zhang W, et al
    Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008 and Rv1667c involved in pyrazinamide resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00940.
    PubMed     Text format     Abstract available
    
    
    
65. SRIVASTAVA S, Magombedze G, Koeuth T, Sherman C, et al
    Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00751.
    PubMed     Text format     Abstract available
    
    
    
66. FOFANA MO, Dowdy DW
    Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    
67. ANTHONY RM, Cynamon M, Hoffner S, Werngren J, et al
    Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    May 2017
68. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
    Pharmacokinetic evidence to support increased doses of rifampin for tuberculosis: results from the HIRIF trial.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00038.
    PubMed     Text format     Abstract available
    
    
    
69. VAN'T BOVENEIND-VRUBLEUSKAYA N, Seuruk T, van Hateren K, van der Laan T, et al
    Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis patients.
    Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00343.
    PubMed     Text format     Abstract available
    
    
    
70. SLOAN DJ, McCallum AD, Schipani A, Egan D, et al
    Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 May 1. pii: AAC.00210.
    PubMed     Text format     Abstract available
    
    
    
71. MOREIRA W, Santhanakrishnan S, Ngan GJY, Low CB, et al
    Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available
    
    
    April 2017
72. NJIRE M, Wang N, Wang B, Tan Y, et al
    Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00070.
    PubMed     Text format     Abstract available
    
    
    
73. VISWANATHAN G, Yadav S, Raghunand TR
    Identification of mycobacterial genes involved in antibiotic sensitivity - Implications in the treatment of tuberculosis with beta-lactam containing regimens.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00425.
    PubMed     Text format     Abstract available
    
    
    
74. OLLIARO PL, Merle C, Mthiyane T, Bah B, et al
    Analysis of the effects on the QT interval of a gatifloxacin-containing regimen versus standard treatment of pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.01834.
    PubMed     Text format     Abstract available
    
    
    
75. DANELISHVILI L, Shulzhenko N, Chinison JJJ, Babrak L, et al
    Mycobacterium tuberculosis proteome response to anti-tuberculosis compounds reveals metabolic "escape" pathways that prolong bacterial survival.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00430.
    PubMed     Text format     Abstract available
    
    
    
76. JANG J, Kim R, Woo M, Jeong J, et al
    Efflux attenuates the anti-bacterial activity of Q203 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02637.
    PubMed     Text format     Abstract available
    
    
    
77. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.00226.
    PubMed     Text format     Abstract available
    
    
    
78. CHEN X, Hashizume H, Tomishige T, Nakamura I, et al
    Delamanid Kills Dormant Mycobacteria in Vitro and in the Guinea Pig Model of Tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.02402.
    PubMed     Text format     Abstract available
    
    
    
79. VAN RIJN SP, Zuur MA, van Altena R, Akkerman OW, et al
    Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available
    
    
    March 2017
80. XU J, Wang B, Hu M, Huo F, et al
    Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00239.
    PubMed     Text format     Abstract available
    
    
    
81. ALSULTAN A, Savic R, Dooley KE, Weiner M, et al
    Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02625.
    PubMed     Text format     Abstract available
    
    
    
82. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
    Erratum for Velasquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    February 2017
83. RAMACHANDRAN G, Kumar AK, Chandrasekaran V, Kannan T, et al
    Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in India.
    Antimicrob Agents Chemother. 2017 Feb 27. pii: AAC.02464.
    PubMed     Text format     Abstract available
    
    
    
84. ROBERTS O, Khoo S, Owen A, Siccardi M, et al
    Interaction of Rifampicin and Darunavir/Ritonavir or Darunavir/Cobicistat In Vitro.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.01776.
    PubMed     Text format     Abstract available
    
    
    
85. KAYIGIRE XA, Friedrich SO, van der Merwe L, Diacon AH, et al
    Acquisition of rifampin resistance in pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02220.
    PubMed     Text format     Abstract available
    
    
    
86. CHOI SR, Britigan BE, Narayanasamy P
    Ga(III) Nanoparticles Inhibit Growth of Both TB and HIV and Release of IL-6 and IL-8 in Co-Infected Macrophages.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02505.
    PubMed     Text format     Abstract available
    
    
    January 2017
87. AJILEYE A, Alvarez N, Merker M, Walker TM, et al
    Some synonymous and non-synonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-resistance results to fluoroquinolones with the Hain GenoType MTBDRsl assays.
    Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02169.
    PubMed     Text format     Abstract available
    
    
    
88. DE JAGER V, van der Merwe L, Venter A, Donald PR, et al
    Time trends in sputum mycobacterial load and 2-day bactericidal activity of INH-containing anti-tuberculosis therapies.
    Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02088.
    PubMed     Text format     Abstract available
    
    
    
89. KUMAR P, Kaushik A, Bell D, Chauhan V, et al
    Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.02234.
    PubMed     Text format     Abstract available
    
    
    
90. VAN ALTENA R, Dijkstra JA, van der Meer ME, Borjas Howard JF, et al
    Reduced chance of hearing loss associated with Therapeutic Drug Monitoring of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.01400.
    PubMed     Text format     Abstract available
    
    
    
91. SCHUMP MD, Fox DM, Bertozzi CR, Riley LW, et al
    Subcellular Partitioning and Intra-Macrophage Selectivity of Antimicrobial Compounds Against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jan 4. pii: AAC.01639.
    PubMed     Text format     Abstract available
    
    
    December 2016
92. IACOBINO A, Piccaro G, Giannoni F, Mustazzolu A, et al
    Mycobacterium tuberculosis is selectively killed by rifampin and rifapentine in hypoxia at neutral pH.
    Antimicrob Agents Chemother. 2016 Dec 19. pii: AAC.02296.
    PubMed     Text format     Abstract available
    
    
    
93. FOFANA MO, Shrestha S, Knight GM, Cohen T, et al
    Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model.
    Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.00498.
    PubMed     Text format     Abstract available
    
    
    
94. PANG Y, Zhang Z, Wang Y, Wang S, et al
    Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000-2010: findings from the national survey data.
    Antimicrob Agents Chemother. 2016 Dec 5. pii: AAC.02170.
    PubMed     Text format     Abstract available
    
    
    November 2016
95. BROSSIER F, Pham A, Bernard C, Aubry A, et al
    Molecular investigation of resistance to second line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01299.
    PubMed     Text format     Abstract available
    
    
    
96. SEBASTIAN J, Swaminath S, Nair RR, Jakkala K, et al
    De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells formed against Antituberculosis Drugs In Vitro.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01343.
    PubMed     Text format     Abstract available
    
    
    
97. YEE M, Gopal P, Dick T
    Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with pyrazinamide resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.02342.
    PubMed     Text format     Abstract available
    
    
    
98. ROSEN BC, Dillon NA, Peterson ND, Minato Y, et al
    Long-Chain Fatty Acyl-CoA Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.02130.
    PubMed     Text format     Abstract available
    
    
    
99. ANTWI S, Yang H, Enimil A, Sarfo AM, et al
    Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01701.
    PubMed     Text format     Abstract available
    
    
    
100. ALFFENAAR JC, Akkerman OW, van Hest R
     Statin Adjunctive Therapy for Tuberculosis Treatment.
     Antimicrob Agents Chemother. 2016;60:7004.
     PubMed     Text format    
     
     
     October 2016
101. PHOLWAT S, Stroup S, Heysell S, Ogarkov O, et al
     Eis C-14G and C-15G mutations do not confer kanamycin resistance in M. tuberculosis.
     Antimicrob Agents Chemother. 2016 Oct 10. pii: AAC.01775.
     PubMed     Text format     Abstract available
     
     
     September 2016
102. WANG X, Yang S, Gu J, Deng J, et al
     Mycobacterium tuberculosis arylamine N-acetyltransferase acetylates and thus inactivates para-aminosalicylic acid.
     Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.01312.
     PubMed     Text format     Abstract available
     
     
     
103. LI Y, Wang Y, Zhang Z, Gao H, et al
     Association between embB Codon 306 Mutations, Phenotypic Resistance Profiles and Genotypic Characterization in Clinical Mycobacterium tuberculosis Isolates from Hebei, China.
     Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.00532.
     PubMed     Text format     Abstract available
     
     
     
104. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
     Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in MDR-TB Patients.
     Antimicrob Agents Chemother. 2016 Sep 6. pii: AAC.00632.
     PubMed     Text format     Abstract available
     
     
     August 2016
105. NARAN K, Moosa A, Barry CE 3rd, Boshoff HI, et al
     Bioluminescent reporters for rapid mechanism of action assessment in tuberculosis drug discovery.
     Antimicrob Agents Chemother. 2016 Aug 29. pii: AAC.01178.
     PubMed     Text format     Abstract available
     
     
     
106. ZHANG D, Gomez JE, Chien JY, Haseley N, et al
     Genomic analysis of the evolution of fluoroquinolone resistance in Mycobacterium tuberculosis prior to tuberculosis diagnosis.
     Antimicrob Agents Chemother. 2016 Aug 29. pii: AAC.00664.
     PubMed     Text format     Abstract available
     
     
     
107. FURIN JJ, Du Bois J, van Brakel E, Chheng P, et al
     Early Bactericidal Activity of AZD5847 in Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2016 Aug 22. pii: AAC.01163.
     PubMed     Text format     Abstract available
     
     
     
108. CHUANG YM, Dutta NK, Hung CF, Wu TC, et al
     The stringent response factors PPX1 and PPK2 play an important role in Mycobacterium tuberculosis metabolism, biofilm formation, and sensitivity to isoniazid in vivo.
     Antimicrob Agents Chemother. 2016 Aug 15. pii: AAC.01139.
     PubMed     Text format     Abstract available
     
     
     
109. FOO CS, Lechartier B, Kolly GS, Boy-Rottger S, et al
     Characterization of DprE1-mediated benzothiazinone resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Aug 15. pii: AAC.01523.
     PubMed     Text format     Abstract available
     
     
     
110. NIKONENKO BV, Kornienko A, Majorov K, Ivanov P, et al
     In vitro activity of 3-triazenoindoles against Mycobacterium tuberculosis and Mycobacterium avium.
     Antimicrob Agents Chemother. 2016 Aug 8. pii: AAC.00998.
     PubMed     Text format     Abstract available
     
     
     
111. PALENCIA A, Li X, Bu W, Choi W, et al
     Discovery of novel oral protein synthesis inhibitors of Mycobacterium tuberculosis that target leucyl-tRNA synthetase.
     Antimicrob Agents Chemother. 2016 Aug 8. pii: AAC.01339.
     PubMed     Text format     Abstract available
     
     
     
112. CORDES H, Thiel C, Aschmann HE, Baier V, et al
     A PBPK model of isoniazid and its application in individualizing tuberculosis chemotherapy.
     Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.00508.
     PubMed     Text format     Abstract available
     
     
     
113. ROCKWOOD NN, Meintjes G, Chirehwa M, Wiesner L, et al
     HIV-1 co-infection does not reduce exposure to rifampicin, isoniazid, and pyrazinamide in South African tuberculosis outpatients.
     Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.00480.
     PubMed     Text format     Abstract available
     
     
     
114. PROSSER GA, Rodenburg A, Khoury H, de Chiara C, et al
     Glutamate racemase is the primary target of beta-chloro-D-alanine in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.01249.
     PubMed     Text format     Abstract available
     
     
     July 2016
115. MODONGO C, Pasipanodya JG, Magazi BT, Srivastava S, et al
     Artificial intelligence and amikacin exposures predictive of outcome in multidrug-resistant tuberculosis patients.
     Antimicrob Agents Chemother. 2016 Jul 25. pii: AAC.00962.
     PubMed     Text format     Abstract available
     
     
     
116. GARCIA-GARCIA V, Oldfield E, Benaim G
     Inhibition of Leishmania mexicana Growth by the Tuberculosis Drug SQ109.
     Antimicrob Agents Chemother. 2016 Jul 25. pii: AAC.00945.
     PubMed     Text format     Abstract available
     
     
     
117. SRIVASTAVA S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, et al
     Amikacin optimal exposures targets in the hollow fiber system model of tuberculosis.
     Antimicrob Agents Chemother. 2016 Jul 25. pii: AAC.00961.
     PubMed     Text format     Abstract available
     
     
     
118. SHAH S, Dalecki AG, Malalasekera AP, Crawford CL, et al
     8-Hydroxyquinolines are boosting-agents of copper related toxicity in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Jul 18. pii: AAC.00325.
     PubMed     Text format     Abstract available
     
     
     June 2016
119. YU X, Wang G, Chen S, Wei G, et al
     Mycobacterium tuberculosis wild-type and non-wild-type MIC distributions for the novel fluoroquinolone antofloxacin compared with ofloxacin, levofloxacin, and moxifloxacin.
     Antimicrob Agents Chemother. 2016 Jun 20. pii: AAC.00393.
     PubMed     Text format     Abstract available
     
     
     
120. DISRATTHAKIT A, Prammananan T, Tribuddharat C, Thaipisuttikul I, et al
     Gyrase Mutations in Pre-extensively and Extensively Drug-resistant Tuberculosis in Thai Clinical Isolates: Insights into the Role of gyrB Mutations in Quinolone Resistance.
     Antimicrob Agents Chemother. 2016 Jun 13. pii: AAC.00539.
     PubMed     Text format     Abstract available
     
     
     
121. LI W, Obregon-Henao A, Wallach JB, North EJ, et al
     Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3.
     Antimicrob Agents Chemother. 2016 Jun 13. pii: AAC.00826.
     PubMed     Text format     Abstract available
     
     
     
122. LI D, Hu Y, Werngren J, Mansjo M, et al
     Emergence and genetic characteristics of pyrazinamide resistant tuberculosis in China, a multi-center study.
     Antimicrob Agents Chemother. 2016 Jun 13. pii: AAC.02687.
     PubMed     Text format     Abstract available
     
     
     
123. DEN HERTOG AL, Menting S, Pfeltz R, Warns M, et al
     PZA is active against Mycobacterium tuberculosis cultures at neutral pH with reduced temperature.
     Antimicrob Agents Chemother. 2016 Jun 6. pii: AAC.00654.
     PubMed     Text format     Abstract available
     
     
     May 2016
124. ZHENG X, Zheng R, Hu Y, Werngren J, et al
     Determination of Minimum Inhibitory Concentration (MIC) Breakpoints for second-line drugs associated with clinical outcomes in multidrug-resistant tuberculosis treatment in China.
     Antimicrob Agents Chemother. 2016 May 31. pii: AAC.03008.
     PubMed     Text format     Abstract available
     
     
     
125. HU Y, Pertinez H, Ortega-Muro F, Alameda-Martin L, et al
     Investigation of elimination rate, persistent subpopulation removal and relapse rates of Mycobacterium tuberculosis by combinations of first-line drugs in a modified Cornell mouse model.
     Antimicrob Agents Chemother. 2016 May 23. pii: AAC.02548.
     PubMed     Text format     Abstract available
     
     
     
126. CHIEN JY, Chien ST, Chiu WY, Yu CJ, et al
     Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-resistant Multidrug-resistant Tuberculosis.
     Antimicrob Agents Chemother. 2016 May 23. pii: AAC.00425.
     PubMed     Text format     Abstract available
     
     
     
127. ALMEIDA D, Ioerger T, Tyagi S, Li SY, et al
     Mutations in pepQ Confer Low-level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 May 16. pii: AAC.00753.
     PubMed     Text format     Abstract available
     
     
     
128. NIGHTINGALE S, Chau TT, Fisher M, Nelson M, et al
     Efavirenz and metabolites in CSF; relationship with CYP2B6 c.516G>T genotype and perturbed blood-brain barrier due to tuberculous meningitis.
     Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00280.
     PubMed     Text format     Abstract available
     
     
     
129. LINGARAJU S, Rigouts L, Gupta A, Lee J, et al
     Geographic differences in the contribution of ubiA mutations to high-level Ethambutol Resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 May 2. pii: AAC.03002.
     PubMed     Text format     Abstract available
     
     
     
130. LANOIX JP, Tasneen R, O'Brien P, Sarathy J, et al
     High systemic exposure of pyrazinoic acid has limited anti-tuberculosis activity in murine and rabbit models of tuberculosis.
     Antimicrob Agents Chemother. 2016 May 2. pii: AAC.03085.
     PubMed     Text format     Abstract available
     
     
     April 2016
131. LEE JY, Lee HJ, Kim YK, Yu S, et al
     Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients.
     Antimicrob Agents Chemother. 2016 Apr 18. pii: AAC.01749.
     PubMed     Text format     Abstract available
     
     
     
132. GEORGHIOU SB, Seifert M, Catanzaro D, Garfein RS, et al
     Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.
     Antimicrob Agents Chemother. 2016 Apr 18. pii: AAC.00222.
     PubMed     Text format     Abstract available
     
     
     
133. ALSAAD N, Dijkstra JA, Akkerman OW, de Lange WC, et al
     A pharmacokinetic evaluation of sulfamethoxazole 800 mg once daily in the treatment of tuberculosis.
     Antimicrob Agents Chemother. 2016 Apr 11. pii: AAC.02175.
     PubMed     Text format     Abstract available
     
     
     
134. EARLY JV, Casey A, Martinez-Grau MA, Valcarcel IC, et al
     Oxadiazoles have butyrate-specific conditional activity against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Apr 4. pii: AAC.02896.
     PubMed     Text format     Abstract available
     
     
     March 2016
135. MORADIGARAVAND D, Grandjean L, Martinez E, Li H, et al
     DfrA-thyA double deletion in para-aminosalicylic acid resistant Mycobacterium tuberculosis Beijing strains.
     Antimicrob Agents Chemother. 2016 Mar 28. pii: AAC.00253.
     PubMed     Text format     Abstract available
     
     
     
136. PARVEZ MM, Jung JA, Shin HJ, Kim DH, et al
     Characterization of 22 anti-tuberculosis drugs for the inhibitory interaction potential on organic anionic transporter polypeptides (OATPs) mediated uptake.
     Antimicrob Agents Chemother. 2016 Mar 14. pii: AAC.02765.
     PubMed     Text format     Abstract available
     
     
     
137. STINSON K, Kurepina N, Venter A, Fujiwara M, et al
     Minimum Inhibitory Concentration of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
     Antimicrob Agents Chemother. 2016 Mar 14. pii: AAC.03014.
     PubMed     Text format     Abstract available
     
     
     
138. MAKAFE GG, Cao Y, Tan Y, Julius M, et al
     Oxazolidinone Resistance in Mycobacterium tuberculosis: What is the Role of Cys154Arg Mutation in the Ribosomal Protein L3?
     Antimicrob Agents Chemother. 2016 Mar 7. pii: AAC.00152.
     PubMed     Text format     Abstract available
     
     
     February 2016
139. SRIVASTAVA S, van Rijn SP, Wessels AM, Alffenaar JC, et al
     Susceptibility testing of antibiotics that degrade faster than the doubling-time of slow growing Mycobacteria; Ertapenem sterilizing effect versus Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Feb 29. pii: AAC.02924.
     PubMed     Text format     Abstract available
     
     
     
140. SWANSON R, Ammerman N, Ngcobo B, Adamson J, et al
     Clofazimine contributes sustained antimicrobial activity after treatment cessation in the mouse model of tuberculosis chemotherapy.
     Antimicrob Agents Chemother. 2016 Feb 29. pii: AAC.00177.
     PubMed     Text format     Abstract available
     
     
     
141. HENDON-DUNN CL, Doris KS, Thomas SR, Allnutt JC, et al
     A flow cytometry method for rapidly assessing M. tuberculosis responses to antibiotics with different modes of action.
     Antimicrob Agents Chemother. 2016 Feb 22. pii: AAC.02712.
     PubMed     Text format     Abstract available
     
     
     
142. LI QJ, Jiao WW, Yin QQ, Xu F, et al
     Compensatory Mutations of Rifampicin Resistance Are Associated with Transmission of Multidrug Resistant Mycobacterium tuberculosis Beijing genotype strains in China.
     Antimicrob Agents Chemother. 2016 Feb 22. pii: AAC.02358.
     PubMed     Text format     Abstract available
     
     
     
143. PEARSON CS, Kloos Z, Murray B, Tabe E, et al
     Combined Bioinformatic and Rational Design Approach to Develop Antimicrobial Peptides against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Feb 22. pii: AAC.00940.
     PubMed     Text format     Abstract available
     
     
     
144. SCHERR N, Pluschke G, Panda M
     A comparative study of activities of a diverse set of anti-mycobacterial agents against Mycobacterium tuberculosis and Mycobacterium ulcerans.
     Antimicrob Agents Chemother. 2016 Feb 16. pii: AAC.02658.
     PubMed     Text format     Abstract available
     
     
     
145. TURAPOV O, O'Connor BD, Sarybaeva AA, Williams C, et al
     Phenotypically adapted Mycobacterium tuberculosis populations from sputum are tolerant to first line drugs.
     Antimicrob Agents Chemother. 2016 Feb 16. pii: AAC.01380.
     PubMed     Text format     Abstract available
     
     
     
146. DAS MK, Arya R, Debnath S, Debnath R, et al
     Global urine metabolomics of first line tuberculosis drug treated patients and identification of a novel metabolite of ethambutol.
     Antimicrob Agents Chemother. 2016 Feb 1. pii: AAC.02586.
     PubMed     Text format     Abstract available
     
     
     January 2016
147. ZHANG S, Chen J, Cui P, Shi W, et al
     Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.
     Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02941.
     PubMed     Text format     Abstract available
     
     
     
148. BEKKER A, Schaaf HS, Draper HR, van der Laan L, et al
     The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants dosed at revised WHO-recommended treatment guidelines.
     Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02600.
     PubMed     Text format     Abstract available
     
     
     
149. CHIEN JY, Chiu WY, Chien ST, Chiang CJ, et al
     Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-resistant Mycobacterium tuberculosis Isolates.
     Antimicrob Agents Chemother. 2016 Jan 19. pii: AAC.01049.
     PubMed     Text format     Abstract available
     
     
     
150. NUERMBERGER E, Sizemore C, Romero K, Hanna D, et al
     Towards an evidence-based non-clinical roadmap for evaluating the efficacy of new TB drug regimens: Proceedings of a Critical Path to TB Drug Regimens (CPTR)-National Institute of Allergy and Infectious Disease (NIAID) in vivo Pharmacology Workshop fo
     Antimicrob Agents Chemother. 2016 Jan 11. pii: AAC.02041.
     PubMed     Text format     Abstract available
     
     
     December 2015
151. LANOIX JP, Betoudji F, Nuermberger E
     Sterilizing activity of pyrazinamide in combination with first-line drugs in a C3HeB/FeJ mouse model of tuberculosis.
     Antimicrob Agents Chemother. 2015 Dec 7. pii: AAC.02637.
     PubMed     Text format     Abstract available
     
     
     
152. DENTI P, Martinson N, Cohn S, Mashabela F, et al
     Population pharmacokinetics of rifampicin in pregnant women with tuberculosis and HIV co-infection in Soweto, South Africa.
     Antimicrob Agents Chemother. 2015 Dec 7. pii: AAC.02051.
     PubMed     Text format     Abstract available
     
     
     November 2015
153. LANOIX JP, Ioerger T, Ormond A, Kaya F, et al
     Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum.
     Antimicrob Agents Chemother. 2015 Nov 16. pii: AAC.01370.
     PubMed     Text format     Abstract available
     
     
     
154. CHIREHWA MT, Rustomjee R, Mthiyane T, Onyebujoh P, et al
     Model-based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of hepatic extraction.
     Antimicrob Agents Chemother. 2015 Nov 9. pii: AAC.01830.
     PubMed     Text format     Abstract available
     
     
     
155. LEE H, Jeong BH, Park HY, Jeon K, et al
     Treatment Outcomes of Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2015 Nov 2. pii: AAC.01377.
     PubMed     Text format     Abstract available
     
     
     
156. ZHANG D, Wang Y, Lu J, Pang Y, et al
     In vitro activity of beta-lactams in combination with beta-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis isolates.
     Antimicrob Agents Chemother. 2015 Nov 2. pii: AAC.01035.
     PubMed     Text format     Abstract available
     
     
     October 2015
157. SORRENTINO F, Gonzalez Del Rio R, Zheng X, Presa JM, et al
     Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages.
     Antimicrob Agents Chemother. 2015 Oct 26. pii: AAC.01920.
     PubMed     Text format     Abstract available
     
     
     
158. TASNEEN R, Betoudji F, Tyagi S, Li SY, et al
     Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis.
     Antimicrob Agents Chemother. 2015 Oct 26. pii: AAC.01691.
     PubMed     Text format     Abstract available
     
     
     
159. HENNIG S, Naiker S, Reddy T, Egan D, et al
     The effect of SLCO1B1 polymorphisms on the pharmacokinetics of rifabutin in African HIV-infected patients with tuberculosis.
     Antimicrob Agents Chemother. 2015 Oct 19. pii: AAC.01195.
     PubMed     Text format     Abstract available
     
     
     
160. PARK JS, Lee JY, Lee YJ, Kim SJ, et al
     Serum levels of anti-tuberculosis drugs and their effect on tuberculosis treatment outcome.
     Antimicrob Agents Chemother. 2015 Oct 12. pii: AAC.00693.
     PubMed     Text format     Abstract available
     
     
     
161. MEDELLIN-GARIBAY SE, Cortez-Espinosa N, Milan-Segovia RC, Magana-Aquino M, et al
     CLINICAL PHARMACOKINETICS OF RIFAMPICIN IN PATIENTS WITH TUBERCULOSIS AND TYPE 2 DIABETES MELLITUS: ASSOCIATION WITH BIOCHEMICAL AND IMMUNOLOGICAL PARAMETERS.
     Antimicrob Agents Chemother. 2015 Oct 5. pii: AAC.01067.
     PubMed     Text format     Abstract available
     
     
     
162. PIRES D, Valente E, Simoes MF, Carmo N, et al
     Esters of pyrazinoic acid are active against pyrazinamide-resistant strains of Mycobacterium tuberculosis and other naturally resistant mycobacteria in vitro and ex vivo within macrophages.
     Antimicrob Agents Chemother. 2015 Oct 5. pii: AAC.00936.
     PubMed     Text format     Abstract available
     
     
     
163. MAIGA MC, Ahmadou Ahidjo B, Maiga M, Bishai WR, et al
     Roflumilast, a type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis.
     Antimicrob Agents Chemother. 2015 Oct 5. pii: AAC.02145.
     PubMed     Text format     Abstract available
     
     
     September 2015
164. RUEDA J, Realpe T, Mejia GI, Zapata E, et al
     Genotypic analysis of genes associated with independent and cross-resistance to Isoniazid and Ethionamide in M. tuberculosis clinical isolates.
     Antimicrob Agents Chemother. 2015 Sep 14. pii: AAC.01028.
     PubMed     Text format     Abstract available
     
     
     
165. PETERSON ND, Rosen BC, Dillon NA, Baughn AD, et al
     Uncoupling environmental pH and intrabacterial acidification from pyrazinamide susceptibility in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2015 Sep 14. pii: AAC.00967.
     PubMed     Text format     Abstract available
     
     
     August 2015
166. HEYSELL SK, Pholwat S, Mpagama SG, Pazia SJ, et al
     Sensititre MYCOTB plate compared to Bactec MGIT 960 for first and second-line anti-tuberculosis drug susceptibility testing in Tanzania: a call to operationalize minimum inhibitory concentrations.
     Antimicrob Agents Chemother. 2015 Aug 24. pii: AAC.01117.
     PubMed     Text format     Abstract available
     
     
     
167. WINGLEE K, Lun S, Pieroni M, Kozikowski A, et al
     Mutation of Rv2887, a marR-like gene, confers Mycobacterium tuberculosis resistance to an imidazopyridine-based agent.
     Antimicrob Agents Chemother. 2015 Aug 24. pii: AAC.01341.
     PubMed     Text format     Abstract available
     
     
     
168. KAUSHIK A, Makkar N, Pandey P, Parrish N, et al
     Carbapenems and Rifampicin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2015 Aug 10. pii: AAC.01158.
     PubMed     Text format     Abstract available
     
     
     
169. GOLD B, Roberts J, Ling Y, Lopez Quezada L, et al
     Rapid, semi-quantitative assay to discriminate among compounds with activity against replicating or non-replicating Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2015 Aug 3. pii: AAC.00803.
     PubMed     Text format     Abstract available
     
     
     July 2015
170. VAN OOSTERHOUT JJ, Dzinjalamala FK, Dimba A, Waterhouse D, et al
     Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi.
     Antimicrob Agents Chemother. 2015 Jul 27. pii: AAC.01193.
     PubMed     Text format     Abstract available
     
     
     
171. MODONGO C, Pasipanodya JG, Zetola NM, Williams SM, et al
     Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients.
     Antimicrob Agents Chemother. 2015 Jul 27. pii: AAC.01050.
     PubMed     Text format     Abstract available
     
     
     
172. VERDUGO D, Fallows D, Ahuja S, Schluger N, et al
     Epidemiologic correlates of pyrazinamide resistant Mycobacterium tuberculosis in New York City.
     Antimicrob Agents Chemother. 2015 Jul 20. pii: AAC.00764.
     PubMed     Text format     Abstract available
     
     
     
173. GARCIA-PRATS AJ, Draper HR, Thee S, Dooley KE, et al
     The pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis.
     Antimicrob Agents Chemother. 2015 Jul 20. pii: AAC.01404.
     PubMed     Text format     Abstract available
     
     
     
174. OGWANG S, Good C, Okware B, Nsereko M, et al
     Sulfamethoxazole Susceptibility of Mycobacterium tuberculosis Isolates from HIV-infected Ugandan Adults with Tuberculosis Taking Trimethoprim-Sulfamethoxazole Prophylaxis.
     Antimicrob Agents Chemother. 2015 Jul 13. pii: AAC.01101.
     PubMed     Text format     Abstract available
     
     
     
175. DEMARCO VP, Ordonez AA, Klunk M, Prideaux B, et al
     Determination of 11C-Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice Using Dynamic Positron Emission Tomography Bioimaging.
     Antimicrob Agents Chemother. 2015 Jul 13. pii: AAC.01146.
     PubMed     Text format     Abstract available
     
     
     
176. SOROKA D, Li de la Sierra-Gallay I, Dubee V, Triboulet S, et al
     Hydrolysis of clavulanate by Mycobacterium tuberculosis beta-lactamase BlaC harboring a canonic SDN motif.
     Antimicrob Agents Chemother. 2015 Jul 6. pii: AAC.00598.
     PubMed     Text format     Abstract available
     
     
     
177. SINGH R, Ramachandran V, Shandil R, Sharma S, et al
     In silico based high through put screen for discovery of novel combinations for the treatment for tuberculosis.
     Antimicrob Agents Chemother. 2015 Jul 6. pii: AAC.05148.
     PubMed     Text format     Abstract available
     
     
     June 2015
178. CUEVAS-CORDOBA B, Juarez Eusebio DM, Almaraz-Velazco R, Muniz-Salazar R, et al
     Mutation at embB 306, a potential marker for the identification of multidrug resistance associated with ethambutol in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2015 Jun 29. pii: AAC.00117.
     PubMed     Text format     Abstract available
     
     
     
179. WILLBY M, Sikes RD, Malik S, Metchock B, et al
     Correlation between GyrA mutations and ofloxacin, levofloxacin and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2015 Jun 22. pii: AAC.00662.
     PubMed     Text format     Abstract available
     
     
     
180. HAVER HL, Chua A, Ghode P, Lakshminarayana SB, et al
     Mutations in the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro selected PA-824 mutants of Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2015 Jun 22. pii: AAC.00308.
     PubMed     Text format     Abstract available
     
     
     
181. RAMIREZ-BUSBY SM, Valafar F
     A Systematic Review of Mutations in Pyrazinamidase Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis Clinical Isolates.
     Antimicrob Agents Chemother. 2015 Jun 15. pii: AAC.00204.
     PubMed     Text format     Abstract available
     
     
     
182. STURKENBOOM MG, Mulder LW, de Jager A, van Altena R, et al
     Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.
     Antimicrob Agents Chemother. 2015 Jun 8. pii: AAC.00756.
     PubMed     Text format     Abstract available
     
     
     
183. DALECKI AG, Haeili M, Shah S, Speer A, et al
     Disulfiram and copper ions kill Mycobacterium tuberculosis in a synergistic manner.
     Antimicrob Agents Chemother. 2015 Jun 1. pii: AAC.00692.
     PubMed     Text format     Abstract available
     
     
     
184. BROSSIER F, Sougakoff W, Bernard C, Petrou M, et al
     Molecular analysis of the embCAB locus and embR gene involved in resistance to ethambutol in clinical isolates of Mycobacterium tuberculosis in France.
     Antimicrob Agents Chemother. 2015 Jun 1. pii: AAC.00150.
     PubMed     Text format     Abstract available
     
     
     
185. MINATO Y, Thiede JM, Kordus SL, McKlveen EJ, et al
     Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.
     Antimicrob Agents Chemother. 2015 Jun 1. pii: AAC.00647.
     PubMed     Text format     Abstract available
     
     
     May 2015
186. LECHARTIER B, Cole ST
     Insight into the mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2015 May 18. pii: AAC.00395.
     PubMed     Text format     Abstract available
     
     
     
187. PARK SI, Oh J, Jang K, Yoon J, et al
     Pharmacokinetics of Second-line Anti-Tuberculosis Drugs after Multiple Administrations in Healthy Volunteers.
     Antimicrob Agents Chemother. 2015 May 18. pii: AAC.00354.
     PubMed     Text format     Abstract available
     
     
     
188. MAKAROV V, Neres J, Hartkoorn RC, Ryabova OB, et al
     8-Pyrrole-benzothiazinones non-covalent inhibitors of DprE1 from Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2015 May 18. pii: AAC.00778.
     PubMed     Text format     Abstract available
     
     
     
189. JOHNSON BK, Colvin CJ, Needle DB, Mba Medie F, et al
     The carbonic anhydrase inhibitor ethoxzolamide inhibits the Mycobacterium tuberculosis PhoPR regulon, Esx-1 secretion and attenuates virulence.
     Antimicrob Agents Chemother. 2015 May 18. pii: AAC.00719.
     PubMed     Text format     Abstract available
     
     
     
190. SY SK, de Kock L, Diacon AH, Werely CJ, et al
     N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in drug-resistant pulmonary tuberculosis patients.
     Antimicrob Agents Chemother. 2015 May 11. pii: AAC.04049.
     PubMed     Text format     Abstract available
     
     
     February 2015
191. GUMBO T, Pasipanodya JG, Wash P, Burger A, et al
     Reply to "breakpoints and drug exposure are inevitably closely linked".
     Antimicrob Agents Chemother. 2015;59:1385.
     PubMed     Text format    
     
     
     
192. ALFFENAAR JW, Akkerman OW, Bolhuis MS, Boeree MJ, et al
     Breakpoints and drug exposure are inevitably closely linked.
     Antimicrob Agents Chemother. 2015;59:1384.
     PubMed     Text format    
     
     
     December 2014
193. RAMACHANDRAN G, Kumar AK, Bhavani PK, Kannan T, et al
     Pharmacokinetics of first-line anti-TB drugs in HIV-infected children with TB treated with intermittent regimens in India.
     Antimicrob Agents Chemother. 2014 Dec 8. pii: AAC.04338.
     PubMed     Text format     Abstract available
     
     
     September 2014
194. REQUENA-MENDEZ A, Davies G, Waterhouse D, Ardrey A, et al
     Effect of dosage, co-morbidities and food on pharmacokinetics of isoniazid in Peruvian TB patients.
     Antimicrob Agents Chemother. 2014 Sep 15. pii: AAC.03258.
     PubMed     Text format     Abstract available
     
     
     August 2014
195. SVENSSON EM, Dooley KE, Karlsson MO
     Impact of lopinavir/ritonavir or nevirapine on bedaquiline exposures: potential implications for patients with TB/HIV co-infection.
     Antimicrob Agents Chemother. 2014 Aug 11. pii: AAC.03246.
     PubMed     Text format     Abstract available
     
     
     
196. SUN F, Ruan Q, Wang J, Chen S, et al
     Linezolid manifests a rapid and dramatic therapeutic effect for patients with life threatening tuberculous meningitis.
     Antimicrob Agents Chemother. 2014 Aug 4. pii: AAC.02784.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: